Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology.

Yang I, Han SJ, Sughrue ME, Tihan T, Parsa AT.

J Neurosurg. 2011 Sep;115(3):505-11. doi: 10.3171/2011.4.JNS101172. Epub 2011 Jun 10.

PMID:
21663411
2.

Effect of NKG2D ligand expression on host immune responses.

Champsaur M, Lanier LL.

Immunol Rev. 2010 May;235(1):267-85. doi: 10.1111/j.0105-2896.2010.00893.x. Review.

3.

Metronomic chemotherapy: new rationale for new directions.

Pasquier E, Kavallaris M, André N.

Nat Rev Clin Oncol. 2010 Aug;7(8):455-65. doi: 10.1038/nrclinonc.2010.82. Epub 2010 Jun 8. Review.

PMID:
20531380
4.

Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis.

Chen CA, Ho CM, Chang MC, Sun WZ, Chen YL, Chiang YC, Syu MH, Hsieh CY, Cheng WF.

Mol Ther. 2010 Jun;18(6):1233-43. doi: 10.1038/mt.2010.34. Epub 2010 Apr 6.

5.

Pigment epithelium-derived factor stimulates tumor macrophage recruitment and is downregulated by the prostate tumor microenvironment.

Halin S, Rudolfsson SH, Doll JA, Crawford SE, Wikström P, Bergh A.

Neoplasia. 2010 Apr;12(4):336-45.

6.

Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme.

Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, Leenders WP, van Furth WR.

BMC Cancer. 2009 Dec 16;9:444. doi: 10.1186/1471-2407-9-444. Review.

7.

Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.

Daenen LG, Shaked Y, Man S, Xu P, Voest EE, Hoffman RM, Chaplin DJ, Kerbel RS.

Mol Cancer Ther. 2009 Oct;8(10):2872-81. doi: 10.1158/1535-7163.MCT-09-0583.

8.

Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation.

Tanaka H, Matsushima H, Nishibu A, Clausen BE, Takashima A.

Cancer Res. 2009 Sep 1;69(17):6987-94. doi: 10.1158/0008-5472.CAN-09-1106. Epub 2009 Aug 25.

9.

Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression.

Johnson B, Osada T, Clay T, Lyerly H, Morse M.

Curr Mol Med. 2009 Aug;9(6):702-7. Review.

PMID:
19689297
10.

Oncogenic stress sensed by the immune system: role of natural killer cell receptors.

Raulet DH, Guerra N.

Nat Rev Immunol. 2009 Aug;9(8):568-80. doi: 10.1038/nri2604. Review.

11.

Cell death mechanisms induced by cytotoxic lymphocytes.

Chávez-Galán L, Arenas-Del Angel MC, Zenteno E, Chávez R, Lascurain R.

Cell Mol Immunol. 2009 Feb;6(1):15-25. doi: 10.1038/cmi.2009.3. Review.

12.

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.

Loges S, Mazzone M, Hohensinner P, Carmeliet P.

Cancer Cell. 2009 Mar 3;15(3):167-70. doi: 10.1016/j.ccr.2009.02.007. Review.

13.

Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.

Banissi C, Ghiringhelli F, Chen L, Carpentier AF.

Cancer Immunol Immunother. 2009 Oct;58(10):1627-34. doi: 10.1007/s00262-009-0671-1. Epub 2009 Feb 17.

PMID:
19221744
14.

Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib.

Ma J, Waxman DJ.

Clin Cancer Res. 2009 Jan 15;15(2):578-88. doi: 10.1158/1078-0432.CCR-08-1174.

15.

Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.

Ma J, Waxman DJ.

Mol Cancer Ther. 2008 Dec;7(12):3670-84. doi: 10.1158/1535-7163.MCT-08-0715. Review.

16.

Regulation of dendritic cell migration by CD74, the MHC class II-associated invariant chain.

Faure-André G, Vargas P, Yuseff MI, Heuzé M, Diaz J, Lankar D, Steri V, Manry J, Hugues S, Vascotto F, Boulanger J, Raposo G, Bono MR, Rosemblatt M, Piel M, Lennon-Duménil AM.

Science. 2008 Dec 12;322(5908):1705-10. doi: 10.1126/science.1159894.

17.

Chemotherapy induces tumor clearance independent of apoptosis.

Guerriero JL, Ditsworth D, Fan Y, Zhao F, Crawford HC, Zong WX.

Cancer Res. 2008 Dec 1;68(23):9595-600. doi: 10.1158/0008-5472.CAN-08-2452.

18.

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL.

Clin Cancer Res. 2008 Nov 15;14(22):7272-83. doi: 10.1158/1078-0432.CCR-08-0652.

19.

Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells.

Martin-Manso G, Galli S, Ridnour LA, Tsokos M, Wink DA, Roberts DD.

Cancer Res. 2008 Sep 1;68(17):7090-9. doi: 10.1158/0008-5472.CAN-08-0643.

20.

Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones.

Chou TC, Zhang X, Zhong ZY, Li Y, Feng L, Eng S, Myles DR, Johnson R Jr, Wu N, Yin YI, Wilson RM, Danishefsky SJ.

Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13157-62. doi: 10.1073/pnas.0804773105. Epub 2008 Aug 28.

Supplemental Content

Support Center